Abstract
Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias, gliomas and even non-small-cell lung cancers, especially when administered in combination with taxanes. It is possible that the critical target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.
MeSH terms
-
Alkyl and Aryl Transferases / antagonists & inhibitors*
-
Alkyl and Aryl Transferases / metabolism
-
Animals
-
Drug Delivery Systems / methods*
-
Drug Delivery Systems / trends
-
Enzyme Inhibitors / therapeutic use*
-
Farnesyltranstransferase
-
Genes, ras / drug effects
-
Genes, ras / physiology
-
Humans
-
Neoplasms / drug therapy
-
Neoplasms / enzymology
Substances
-
Enzyme Inhibitors
-
Alkyl and Aryl Transferases
-
Farnesyltranstransferase